CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases

CBL 在肺癌中经常发生改变:其与 MET 和 EGFR 酪氨酸激酶突变的关系

阅读:16
作者:Yi-Hung Carol Tan, Soundararajan Krishnaswamy, Suvobroto Nandi, Rajani Kanteti, Sapana Vora, Kenan Onel, Rifat Hasina, Fang-Yi Lo, Essam El-Hashani, Gustavo Cervantes, Matthew Robinson, Han-Shui Hsu, Stephen C Kales, Stanley Lipkowitz, Theodore Karrison, Martin Sattler, Everett E Vokes, Yi-Ching Wan

Background

Non-small cell lung cancer (NSCLC) is a heterogeneous group of disorders with a number of genetic and proteomic alterations. c-CBL is an E3 ubiquitin ligase and adaptor molecule important in normal homeostasis and cancer. We determined the genetic variations of c-CBL, relationship to receptor tyrosine kinases (EGFR and MET), and functionality in NSCLC.

Conclusions

Taking the overall mutation rate of c-CBL to be a combination as somatic missense mutation and LOH, it is clear that c-CBL is highly mutated in lung cancers and may play an essential role in lung tumorigenesis and metastasis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。